CureVac N.V. (NASDAQ:CVAC)
| Market Cap | 1.43B |
|---|---|
| Revenue | 0 |
| Gross Profit | 0 |
| Shares Out | 221.98M |
| EPS (ttm) | |
| PE Ratio | 0.0000 |
| Forward PE | -5.7852 |
| Dividend Rate (ttm) | 0.0000 |
| Dividend Yield | 0.0000 |
| Trading Day | Mar 24 |
|---|---|
| Last Price | $6.44 |
| Previous Close | $6.53 |
| Change ($) | -0.09 |
| Change (%) | -1.38% |
| Day's Open | 6.49 |
| Day's Range | 6.33 - 6.58 |
| Day's Volume | 570.29K |
| 52 Week Range | 5.63 - 20.45 |
About CureVac N.V.
CureVac N.V. operates as a global clinical-stage biopharmaceutical company.
The Company focuses on developing a new class of transformative medicines based on messenger ribonucleic acid that has the potential to improve the lives of people. CureVac serves customers worldwide.
News
Quick info
Tuebingen
Baden Wuerttemberg
72076
CureVac N.V. dividends
Total Valuation
CureVac N.V. has a market cap or net worth of $1.43 billion. The enterprise value is $0.
Important Dates
Share Statistics
CureVac N.V. has 221.98 million shares outstanding.
Valuation Ratios
The trailing PE ratio is 0.0000 and the forward PE ratio is -5.7852. CureVac N.V.'s PEG ratio is 0.0000.
Stock Price Statistics
The stock price has increased by 0.0829%. The beta is 1.2394, so CureVac N.V.'s price volatility has been higher than the market average.
Income Statement
In the last 12 months, CureVac N.V. had revenue of $0 and earned $0 in profits. Earnings per share was $.